Atlas Trials

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Clinical trial NCT04210037 · TERMINATED

Trial details

NCT number
NCT04210037
Sponsor
Ascentage Pharma Group Inc.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Cancer
Start date
2020-08-20
Primary completion
2021-08-30
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.